The Ion Torrent™ Oncomine™ Dx Target Test is the first CE-IVD solid-tumor biomarker test, based on targeted next-generation sequencing (NGS), which detects key biomarkers that are relevant to currently approved and investigative targeted therapies in solid tumors.

The only solid tumor biomarker test, which can:

- Detect 46 cancer driver gene variants, including EGFR mutations (including L858R, T790M, and exon 19 deletions); BRAF, KRAS, ERBB2, and MET exon 14 skipping mutations; and ALK, ROS1, RET, and NTRK1/2/3 fusions
- Deliver an all-in-one report to support treatment decisions—including multiple drug indication options—enabling time and cost savings
- Deliver results even for challenging small samples, meaning more patients can potentially access targeted therapies
- Enable faster treatment decisions by generating laboratory results in 4 days

Analyze all key biomarkers for EGFR, ALK, BRAF, and ROS1 kinase inhibitors, and many more currently in clinical trials, from one sample, in one report, in 4 days

Figure 1: Oncomine Dx Target Test delivers key biomarkers associated with targeted therapies from one sample, in one test workflow, and one report.
In oncology, most of the drugs in development are precision medicines associated with molecular testing. As such, fast, broad, and accessible genomic profiling is becoming one of the key factors to ensure patients’ access to the therapies they could potentially benefit from.

The 46 gene targets included in the Oncomine Dx Target Test are cancer driver genes which, based on their role in cancer pathogenesis, have the potential to be therapy targets. Many of them are already targets of approved or investigational therapies for solid tumors.

The Oncomine Dx Target Test can help ensure that your lab will be ready to provide you with all of these biomarkers as they become relevant, without the need for additional resources to implement new and emerging tests.

With the Oncomine Dx Target Test, you and your care team are ready for the future